CIMZIA(R) (Certolizumab Pegol) Provides Rapid And Sustained Relief From Signs And Symptoms Of Rheumatoid Arthritis For Two Years

UCB announced results from several Phase III clinical trials evaluating CIMZIA(R) (certolizumab pegol) - the only PEGylated anti-TNF (Tumor Necrosis Factor) - presented at the American College of Rheumatology (ACR) Annual Scientific Meeting.